A US study to evaluate transarterial radioembolization (TARE) in combination with durvalumab and bevacizumab therapy in people with unresectable hepatocellular carcinoma amenable to TARE - EMERALD-Y90

Study identifier:D933GC00002

ClinicalTrials.gov identifier:NCT06040099

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy

Medical condition

Hepatocellular Carcinoma (HCC)

Phase

Phase 2

Healthy volunteers

No

Study drug

Durvalumab, Bevacizumab

Sex

All

Estimated Enrollment

100

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 31 Jan 2024
Estimated Primary Completion Date: 30 Sept 2026
Estimated Study Completion Date: 30 Sept 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria